AR129996A2 - ANTIBODIES DIRECTED AGAINST IL-33 AND THEIR USES - Google Patents
ANTIBODIES DIRECTED AGAINST IL-33 AND THEIR USESInfo
- Publication number
- AR129996A2 AR129996A2 ARP230101921A ARP230101921A AR129996A2 AR 129996 A2 AR129996 A2 AR 129996A2 AR P230101921 A ARP230101921 A AR P230101921A AR P230101921 A ARP230101921 A AR P230101921A AR 129996 A2 AR129996 A2 AR 129996A2
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- diseases
- attenuate
- interaction
- inhibit
- Prior art date
Links
- 102000017761 Interleukin-33 Human genes 0.000 title abstract 9
- 108010067003 Interleukin-33 Proteins 0.000 title abstract 9
- 230000011664 signaling Effects 0.000 abstract 3
- 230000003993 interaction Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 101000998137 Homo sapiens Interleukin-33 Proteins 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 102000045906 human IL33 Human genes 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona anticuerpos que se unen a interleuquina-33 (IL-33) y métodos para usar los mismos. La invención incluye anticuerpos que inhiben o atenúan la señalización mediada por IL-33. Los anticuerpos de la invención pueden funcionar para bloquear la interacción entre IL-33 y ST2. Alternativamente, determinados anticuerpos de la invención inhiben o atenúan la señalización mediada por IL-33 sin bloquear la interacción de IL-33 / ST2. De acuerdo con determinadas realizaciones de la invención, los anticuerpos son anticuerpos completamente humanos que se unen a la IL-33 humana con elevada afinidad. Los anticuerpos de la invención son útiles para el tratamiento de enfermedades y trastornos asociados con la señalización de IL-33 y/o la expresión celular de IL-33, tales como enfermedades inflamatorias, o enfermedades alérgicas.The present invention provides antibodies that bind interleukin-33 (IL-33) and methods of using the same. The invention includes antibodies that inhibit or attenuate IL-33-mediated signaling. The antibodies of the invention may function to block the interaction between IL-33 and ST2. Alternatively, certain antibodies of the invention inhibit or attenuate IL-33-mediated signaling without blocking the IL-33/ST2 interaction. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind human IL-33 with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or cellular expression of IL-33, such as inflammatory diseases, or allergic diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778687P | 2013-03-13 | 2013-03-13 | |
| US202061819018P | 2020-05-03 | 2020-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129996A2 true AR129996A2 (en) | 2024-10-23 |
Family
ID=93378792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230101921A AR129996A2 (en) | 2013-03-13 | 2023-07-21 | ANTIBODIES DIRECTED AGAINST IL-33 AND THEIR USES |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR129996A2 (en) |
-
2023
- 2023-07-21 AR ARP230101921A patent/AR129996A2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015010599A (en) | Anti-il-33 antibodies and uses thereof. | |
| CL2019001043A1 (en) | Anti-il-33 antibodies and uses thereof. | |
| MX2023014569A (en) | ANTI-SIRPA ANTIBODIES. | |
| CO2017002719A2 (en) | Anti-glucagon antibodies | |
| CL2017003404A1 (en) | Antibacterial compounds | |
| CL2017001459A1 (en) | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology | |
| MX2016006709A (en) | Aplnr modulators and uses thereof. | |
| CL2018000829A1 (en) | Human anti-cd19 antibodies with high affinity | |
| UY35258A (en) | ANTI-PDGFR-beta ANTIBODIES AND USES OF THE SAME | |
| AR083044A1 (en) | ANTI-CD48 ANTIBODIES AND USES OF THE SAME | |
| CL2016003056A1 (en) | Sting modulating cyclic dinucleotides; Composition and pharmaceutical combination that includes them and their use for the treatment of diseases such as inflammation, allergic and autoimmune diseases, infectious diseases and cancer. | |
| GT201500317A (en) | COMPOSITIONS AND METHODS TO ALTER THE SIGNALING OF THE SECOND MESSENGER | |
| EA201600473A1 (en) | HUMANIZED ANTIBODIES TO Tau (PS422) AND METHODS OF APPLICATION | |
| MX391159B (en) | Anti-Tigit antigen-binding proteins and methods of using them | |
| MX2018013072A (en) | Tl1a antibodies and uses thereof. | |
| MX2018014456A (en) | ANTIBODIES AGAINST ALPHA-SINUCLEIN AND ITS USES. | |
| CL2017001135A1 (en) | Enhanced antibodies against il-6 | |
| NI201800134A (en) | ANTIBODIES ANTIFACTOR OF COAGULATION XI | |
| MX2023010076A (en) | Ilt7 binding molecules and methods of using the same. | |
| CR20150585A (en) | ANTI-IGF-1R ANTIBODIES WITH ABOLITION OF THE UNION TO THE FCRN AND ITS USE IN THE TREATMENT OF VASCULAR EYE DISEASES | |
| AR129996A2 (en) | ANTIBODIES DIRECTED AGAINST IL-33 AND THEIR USES | |
| AR095235A1 (en) | ANTIBODIES DIRECTED AGAINST IL-33 AND ITS USES | |
| AR111715A1 (en) | ANTI-SIRPa ANTIBODIES | |
| DOP2019000082A (en) | ANTI-IL-33 ANTIBODIES AND USES OF THE SAME | |
| AR094379A1 (en) | ANTI-PDGFR-b ANTIBODIES AND ITS USES |